Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

22.05 -0.48 (-2.11%)
Streaming Delayed Price Updated: 11:21 AM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Shares of Roivant Sciences Jumped This Week ↗
The company's stock benefited from another company's buyout. 
Via The Motley Fool
News headline image
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗
These two biopharma stocks could be poised for a major growth spurt. 
Via The Motley Fool
News headline image
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis ↗
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. 
Via Benzinga
News headline image
These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
News headline image
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom ↗
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
News headline image
Analyst Expectations for Roivant Sciences's Future ↗
 
Via Benzinga
News headline image
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years ↗
 
Via Benzinga
News headline image
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
From Lokavant
Via Business Wire
News headline image
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
From Lokavant
Via Business Wire
News headline image
Expert Ratings for Roivant Sciences ↗
 
Via Benzinga
News headline image
Roivant Sciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
Where Roivant Sciences Stands With Analysts ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
From Covant Therapeutics
Via GlobeNewswire
News headline image
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
News headline image
Why Shares of Roivant Sciences Were Down Tuesday ↗
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. 
Via The Motley Fool
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
News headline image
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
From Roivant Sciences
Via GlobeNewswire
News headline image
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗
 
Via Benzinga
News headline image
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
Via Benzinga
News headline image
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Earnings Scheduled For February 13, 2023 ↗
Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million. 
Via Benzinga
News headline image
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences Announces Proposed Public Offering of Common Shares
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.